Abstract
The biological pharmaceuticals in the Big Pharma has high economic importance, but it development is highly expensive and have high financial risk for the companies (only 30% of all drugs entering clinical testing will ever reach the market). Varieties of expression system are currently being developed and applied in protein-based drug production. Choice of the most appropriate cell line …